All In Biotech

Drug Trial Radar · NCT06588478

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 249 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

249

Planned (sponsor's estimate)

Start

Jan 3, 2025

Primary completion

Jun 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Loxo Oncology, Inc.Eli Lilly (LLY)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • PirtobrutinibDrug

    Administered Orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: Baseline up to 3 years

Locations

129 sites in 18 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers

    Chandler, Arizona · Recruiting

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • City of Hope National Medical Center

    Irvine, California · Recruiting

  • Palo Alto Medical Foundation Research Institute (PAMFRI)

    Palo Alto, California · Recruiting

  • Stanford Cancer Center

    Palo Alto, California · Recruiting

  • Rocky Mountain Cancer Center

    Aurora, Colorado · Recruiting

  • University of Miami Hospital and Clinics, Sylvester Cancer Center

    Miami, Florida · Recruiting

  • City of Hope National Medical Center, Atlanta Cancer Center

    Newnan, Georgia · Recruiting

  • Mission Cancer + Blood

    Waukee, Iowa · Recruiting

  • Saint Elizabeth Medical Center Edgewood

    Edgewood, Kentucky · Recruiting

  • American Oncology Partners, PA

    Bethesda, Maryland · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Gulfport Memorial Hospital

    Gulfport, Mississippi · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • Williamette Valley Cancer Institute & Research Center

    Eugene, Oregon · Recruiting

  • Cancer Care Associates Of York

    York, Pennsylvania · Recruiting

  • USO-Texas Oncology-Central/South Texas

    Austin, Texas · Recruiting

  • Sarah Cannon Research Institute/SCRI

    The Woodlands, Texas · Recruiting

  • USO-Virginia Oncology Associates

    Hampton, Virginia · Recruiting

  • Flinders Medical Centre

    Adelaide, Australia · Recruiting

  • Bankstown-Lidcombe Hospital

    Bankstown, Australia · Recruiting

  • Box Hill Hospital

    Box Hill, Australia · Recruiting

  • Coffs Harbour Health Campus

    Coffs Harbour, Australia · Recruiting

  • Royal Hobart Hospital

    Hobart, Australia · Recruiting

  • ICON Cancer Centre - Kurralta Park

    Kurralta Park, Australia · Recruiting

  • Latrobe Regional Health

    Traralgon, Australia · Recruiting

  • Calvary Mater Newcastle

    Waratah, Australia · Recruiting

  • The Perth Blood Institute - West Perth

    West Perth, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Australia · Recruiting

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • AZ Sint-Jan Brugge-Oostende AV

    Bruges, Belgium · Recruiting

  • UZ Gent

    Ghent, Belgium · Recruiting

  • Groupe Jolimont

    La Louvière, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Clinique Saint Pierre

    Ottignies, Belgium · Recruiting

  • AZ Delta vzw

    Roeselare, Belgium · Recruiting

  • AZ Nikolaas

    Sint-Niklaas, Belgium · Recruiting

  • CHR Verviers - La Tourelle

    Verviers, Belgium · Recruiting

  • Royal Victoria Regional Health Centre

    Barrie, Canada · Recruiting

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.